{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li T"],"funding":["Natural Science Foundation of Zhejiang Province"],"pagination":["295"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10064697"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["<h4>Background</h4>The prognostic value of cytokeratin 19 fragment (CYFRA 21 - 1) and Ki67 in advanced non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) remains to be explored.<h4>Methods</h4>In this study, 983 primary NSCLC patients from January 2016 to December 2019 were retrospectively reviewed. Finally, 117 advanced NSCLC patients with wild-type EGFR and 37 patients with EGFR mutation were included and prognostic value of CYFRA 21 - 1 and Ki67 were also identified.<h4>Results</h4>The patients age, smoking history and the Eastern Corporative Oncology Group (ECOG) performance scores were significantly different between CYFRA21-1 positive and negative groups (p < 0.05), while no significant differences were found in Ki67 high and low groups"],"journal":["BMC cancer"],"pubmed_title":["Prognostic value of CYFRA 21 - 1 and Ki67 in advanced NSCLC patients with wild-type EGFR."],"pmcid":["PMC10064697"],"funding_grant_id":["LY18H200006"],"pubmed_authors":["Zheng XQ","Wang XM","Li T","Luo Z","Yan GL","Fang YY","Xie Q","Sun Y","He JB"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic value of CYFRA 21 - 1 and Ki67 in advanced NSCLC patients with wild-type EGFR.","description":"<h4>Background</h4>The prognostic value of cytokeratin 19 fragment (CYFRA 21 - 1) and Ki67 in advanced non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) remains to be explored.<h4>Methods</h4>In this study, 983 primary NSCLC patients from January 2016 to December 2019 were retrospectively reviewed. Finally, 117 advanced NSCLC patients with wild-type EGFR and 37 patients with EGFR mutation were included and prognostic value of CYFRA 21 - 1 and Ki67 were also identified.<h4>Results</h4>The patients age, smoking history and the Eastern Corporative Oncology Group (ECOG) performance scores were significantly different between CYFRA21-1 positive and negative groups (p < 0.05), while no significant differences were found in Ki67 high and low groups","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-05-29T19:45:53.434Z","creation":"2025-04-04T21:10:09.508Z"},"accession":"S-EPMC10064697","cross_references":{"pubmed":["37004004"],"doi":["10.1186/s12885-023-10767-9"]}}